Is Lurbinectedin Safe During Pregnancy?
Lurbinectedin (brand name Zepzelca) carries significant pregnancy risks and should be avoided. It is classified as pregnancy category D by some sources, indicating positive evidence of human fetal risk, though controlled studies are limited. Animal data show embryofetal toxicity, including malformations and reduced fetal weight at doses below human equivalents.[1]
What Do Product Labeling and Guidelines Say?
The Zepzelca prescribing information states lurbinectedin can cause fetal harm based on its mechanism (DNA damage via transcription inhibition) and animal studies. It advises:
- Avoid use in pregnant women.
- Verify pregnancy status before starting treatment.
- Use effective contraception during therapy and for 6 months after the last dose for females of reproductive potential; males should use contraception for 4 months post-dose.[1][2]
FDA pregnancy registry (1-888-452-9622) monitors outcomes, but no human data contradict the warnings.
Evidence from Animal and Human Studies
- Rodent studies: Doses at 0.4 mg/kg IV (about 1/3 human exposure) caused maternal toxicity, abortions, malformations (e.g., head/neck defects), and decreased fetal viability.[1]
- Human data: No adequate controlled trials exist due to the drug's oncology use (small cell lung cancer). Postmarketing reports are absent or inconclusive, but genotoxic agents like lurbinectedin pose inherent risks.[2]
What Happens If Exposed Accidentally?
Advise immediate counseling. Risks include spontaneous abortion, congenital anomalies, or growth restriction. Termination may be discussed based on gestational age and patient factors. Report to the manufacturer (Jazz Pharmaceuticals) or FDA registry.[1]
Alternatives for Pregnant Patients with SCLC
Standard small cell lung cancer regimens like etoposide/platinum avoid lurbinectedin. Topotecan is sometimes used but also has fetal risks (pregnancy category D). Non-chemo options (e.g., radiation, supportive care) depend on stage. Consult oncology and maternal-fetal medicine specialists; treatment often delays until postpartum.[3]
Contraception and Fertility Considerations